EPHX2 and cardiac hypertrophy: The combination of sEH inhibitors and epoxylipids has been evaluated, where co-treatment reduced ventricular fibrillation and cardiac hypertrophy (Cervenka et al., 2018) and amplified the cardioprotective effect in left ventricular function following MI (Hrdlička et al., 2019).